Filing Analysis
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notice of the earnings release via press release.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The company is an emerging growth company
- Financial results were released via press release (Exhibit 99.1)
AN2 Therapeutics reported the results of its 2026 annual meeting of stockholders held on June 3, 2026. Stockholders elected three Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 3, 2026.
- Quorum was established with 22,741,535 shares represented (63.18% of outstanding shares).
- Elected Class I directors: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
AN2 Therapeutics announced positive results from a 28-day Nonhuman Primate (NHP) efficacy study and a Phase 1 First-in-Human study for its oral CPSF3 inhibitor, AN2-502998, targeting chronic Chagas disease.
📋 Key Facts
- NHP study showed 100% parasite elimination at target exposures attainable in humans, with durable results maintained through four months post-treatment.
- Phase 1 First-in-Human study (NCT07024589) indicated AN2-502998 was generally well tolerated with no dose-limiting toxicities.
- Human plasma exposures achieved were at or above the NHP efficacy thresholds.
- The company identifies a global market of approximately 10 million infected people, including 300,000 in the U.S.
- If approved, the drug would be eligible for an FDA Tropical Disease Priority Review Voucher.
AN2 Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release incorporated by reference in the filing.
📋 Key Facts
- Reported financial results for Q1 ended March 31, 2026
- Information furnished under Item 2.02 Results of Operations and Financial Condition
- Press release included as Exhibit 99.1
AN2 Therapeutics entered into a new $80 million at-the-market (ATM) sales agreement with Jefferies LLC and terminated its previous sales agreement with TD Securities. The company had previously raised approximately $20 million under the terminated agreement.
🚩 Red Flags
- Significant potential dilution of up to $80 million in common stock.
- Frequent reliance on ATM offerings to fund operations, typical of high-burn biotech companies.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on April 9, 2026.
- The agreement allows for the issuance and sale of up to $80 million of common stock.
- Jefferies will receive a commission of up to 3.0% of gross proceeds.
- Terminated a prior Sales Agreement with TD Securities (USA) LLC dated April 6, 2023.
- Under the previous TD Cowen/TD Securities agreement, the company sold 2,502,000 shares for total proceeds of $20,016,251.
AN2 Therapeutics (ANTX) has implemented a comprehensive stock option repricing for all employees, including executive officers and directors, lowering exercise prices to $3.91 per share. This action follows a significant decline in the company's market value, with original exercise prices for some executive options having been as high as $17.88.
🚩 Red Flags
- Significant destruction of shareholder value, with the stock price dropping approximately 78% from previous option grant levels.
- Insiders (NEOs and Board members) are being shielded from the impact of the stock price decline through repricing.
- The inclusion of non-employee Board members in the repricing program can be viewed as a governance concern regarding independent oversight.
📋 Key Facts
- Repricing effective March 19, 2026, for all outstanding options under the 2017 and 2022 Equity Incentive Plans.
- The new exercise price is $3.91, representing the closing price on the Repricing Date.
- CEO Eric Easom had 742,649 options repriced from original strikes ranging from $6.60 to $17.28.
- CLO Joshua Eizen had 142,150 options repriced from original strikes ranging from $14.29 to $17.88.
- CFO Lucy Day had 221,965 options repriced from original strikes ranging from $6.60 to $17.28.
- To benefit from the lower price, holders must remain with the company until the 'Premium End Date' of September 19, 2027, or until a change in control.
AN2 Therapeutics, Inc. announced its financial results for the fourth quarter ended December 31, 2025, via a press release on March 17, 2026.
📋 Key Facts
- The filing reports financial results for the fourth quarter ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The company is an emerging growth company as defined in Rule 405.
AN2 Therapeutics entered into a securities purchase agreement for a private placement (PIPE) expected to raise approximately $40 million in gross proceeds. The deal involves the issuance of 8,245,611 shares of common stock and pre-funded warrants for an additional 5,789,493 shares.
🚩 Red Flags
- Significant dilution to existing shareholders through the issuance of over 14 million share equivalents.
- The company is restricted from issuing further equity for up to 60 days following the closing.
📋 Key Facts
- The private placement includes 8,245,611 shares and 5,789,493 pre-funded warrants.
- The purchase price is $2.85 per share and $2.84999 per pre-funded warrant.
- Aggregate gross proceeds are expected to be approximately $40 million before fees.
- The company must file a resale registration statement within 30 days of the closing date (March 10, 2026).
- The pre-funded warrants have a nominal exercise price of $0.00001 and do not expire.
AN2 Therapeutics, Inc. announced the appointment of Sarah Williams as Vice President, Controller and Principal Accounting Officer, effective February 1, 2026. This transition is part of a cost-savings effort involving an amended employment agreement for CFO Lucy Day.
🚩 Red Flags
- Significant reduction in CFO compensation (approx. 33% decrease) starting April 2026, which may indicate liquidity constraints or aggressive cost-cutting.
📋 Key Facts
- Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.
- Ms. Williams' base salary increased to $310,000 with a 30% target annual bonus.
- Lucy Day (CFO/PFO) will remain in her role but under an amended employment agreement for cost-savings purposes.
- Lucy Day's annual base salary will decrease from $335,400 (current through March 2026) to $223,600 effective April 1, 2026.
- The transition is explicitly linked to the Company's 'cost-savings efforts'.
AN2 Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025.
📋 Key Facts
- The filing was made on November 12, 2025.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- Financial results are for the third quarter ended September 30, 2025.
- A press release containing the full financial details is attached as Exhibit 99.1.
AN2 Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2025.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025
- Filing date: August 12, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
AN2 Therapeutics entered into two exchange agreements with Coastlands Capital Partners LP to issue pre-funded warrants in exchange for existing common stock. These transactions effectively convert equity into warrants that can be exercised at a nominal price of $0.00001 per share.
🚩 Red Flags
- Significant potential dilution: The issuance of warrants for a total of 2.8 million shares at a near-zero exercise price ($0.00001) will significantly dilute existing shareholders upon exercise.
- Non-cash financing/Equity swap: Using common stock to acquire warrants is often indicative of a company's inability to raise traditional cash capital.
📋 Key Facts
- June 17, 2025: Exchange agreement for 2,500,000 shares of common stock for a pre-funded warrant to acquire 2,500,000 shares.
- June 19, 2025: Exchange agreement for 300,000 shares of common stock for a pre-funded warrant to acquire 300,000 shares.
- Total potential dilution from these transactions is 2,800,000 shares via warrants.
- Exercise price per share: $0.00001.
- Warrants include a beneficial ownership blocker (9.99% limit, scalable to 19.99% after 61 days).
- Issuance relied on Section 3(a)(9) exemption from registration.
AN2 Therapeutics, Inc. filed an 8-K to furnish an updated investor presentation via its website on June 11, 2025.
📋 Key Facts
- The company posted an updated investor presentation on the 'Investors' section of its website.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information provided under Item 7.01 is furnished, not filed, meaning it does not carry the same liability as a standard filing.
AN2 Therapeutics, Inc. held its 2025 annual meeting of stockholders on May 22, 2025, to elect Class III directors and ratify the appointment of PricewaterhouseCoopers LLP as independent auditors.
🚩 Red Flags
- High number of withheld/against votes for specific directors (e.g., Stephanie Wong had 9,940,465 votes withheld).
📋 Key Facts
- Annual Meeting held on May 22, 2025.
- Quorum established by 23,928,440 shares (79.50% of outstanding common stock).
- Class III directors Eric Easom, Stephanie Wong, and Joseph Zakrzewski were elected to terms ending in 2028.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2025 with significant majority support (23,736,942 votes for).
- Voting results show varying levels of 'Withheld' or 'Against' votes for individual director nominees.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release issued on May 13, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
AN2 Therapeutics released clinical data from the Phase 3 portion of a previously terminated study (EBO-301) and provided an update on its Boron Chemistry pipeline milestones. The filing serves as a regulatory disclosure for a press release containing significant clinical and strategic updates.
🚩 Red Flags
- The mention of 'previously terminated' study data suggests past clinical setbacks or strategic pivots which may impact investor sentiment depending on the nature of the new data.
📋 Key Facts
- Reported data from the Phase 3 portion of the previously terminated EBO-301 study.
- Outlined future milestones regarding the company's Boron Chemistry pipeline.
- Filed under Item 7.01 (Regulation FD Disclosure) via a press release dated May 1, 2025.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 25, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024. The filing serves as a formal notice that the company's quarterly earnings press release has been issued.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024.
- Filing date: November 13, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and operations.
AN2 Therapeutics, Inc. announced the promotion of Joshua Eizen from Chief Legal Counsel to the dual role of Chief Legal Officer and Chief Operating Officer, effective November 4, 2024.
📋 Key Facts
- Joshua Eizen appointed as Chief Legal Officer (CLO) and Chief Operating Officer (COO) on November 4, 2024.
- Annual salary increased to $450,000.
- Compensation package includes an option to purchase 63,000 shares of common stock and 31,500 restricted stock units (RSUs).
- Stock options vest monthly over 48 months; RSUs vest annually in 25% increments.
- The company confirmed no related-party transactions or family relationships involving the appointee.
AN2 Therapeutics has implemented a 'poison pill' shareholder rights plan (Rights Agreement) triggered by the potential for an entity to acquire 20% or more of the company's common stock without Board approval. The plan allows existing shareholders to purchase highly dilutive preferred stock if a takeover attempt occurs.
🚩 Red Flags
- Implementation of a Poison Pill (Shareholder Rights Plan) typically indicates management is defending against a perceived hostile takeover or unsolicited bid.
- Extreme dilution potential: The Series A Preferred terms (1,000x liquidation/dividend preference) are highly punitive to common shareholders in a change-of-control scenario.
📋 Key Facts
- The Rights Agreement was entered into on August 15, 2024.
- A dividend of one 'Right' per share of common stock will be issued to shareholders of record as of August 29, 2024.
- Rights become exercisable if a person or group acquires 20% or more of the Common Stock (the 'Distribution Date').
- Upon a Distribution Event, non-acquiring holders can purchase Series A Preferred stock at $6.50 per 1/1000th share.
- The Series A Preferred includes extreme anti-takeover provisions: 1,000x liquidation preference and 1,000x dividend multipliers relative to common stock.
- If an 'Acquiring Person' triggers the pill, non-acquiring shareholders can receive Common Stock at a 2x market value premium.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release issued on August 13, 2024.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 13, 2024.
- The filing includes a press release (Exhibit 99.1) containing the financial results.
AN2 Therapeutics is undergoing a massive restructuring, including a 50% workforce reduction and the discontinuation of its lead EBO-301 clinical study due to failed secondary endpoints. The company is shifting strategy to extend operating capital following these setbacks.
🚩 Red Flags
- Discontinuation of lead clinical program (EBO-301) following failed secondary endpoints.
- Massive workforce reduction (50% of staff) indicates significant distress or pivot in business model.
- Explicit mention of the need to 'extend the Company’s operating capital' suggests liquidity concerns/burn rate management.
- Departure of key executive (Chief Medical Officer).
📋 Key Facts
- Reduction in force (RIF) involves approximately 50% of the total employee workforce.
- The RIF is driven by the discontinuation of the EBO-301 study and a need to extend operating capital.
- Estimated restructuring charges are $2-$3 million for severance and termination expenses.
- Chief Medical Officer Paul Eckburg, M.D., will depart effective August 30, 2024, transitioning to a consultant role for up to one year.
- The EBO-301 study failed to meet its key secondary endpoint (sputum culture conversion at Month 6) with no statistically significant difference between treatment and placebo arms (p=0.64).
- RIF is expected to be substantially complete by the end of 2024.
AN2 Therapeutics, Inc. reported the results of its 2024 annual meeting of stockholders held on June 19, 2024. The meeting included the election of three Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditors, and approval of an amendment to the certificate of incorporation regarding officer exculpation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 19, 2024.
- Quorum reached with 23,360,239 shares (78.31% of outstanding shares) present.
- Margaret FitzPatrick, Patricia Martin, and Melvin Spigelman, M.D. were elected to the Board of Directors.
- PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for fiscal year 2024.
- Stockholders approved an amendment/restatement of the Certificate of Incorporation to provide for officer exculpation under Delaware law.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the release of their periodic financial performance data.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period covered: Fourth quarter and year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is an emerging growth company.
AN2 Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of the release of their quarterly earnings press release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: March 28, 2024.
- The company is an emerging growth company.
- Financial results were released via a press release attached as Exhibit 99.1.
AN2 Therapeutics has voluntarily paused enrollment in its Phase 3 clinical trial for epetraborole (EBO-301) due to interim data suggesting potentially lower than expected efficacy. The pause is intended to allow for further data review and an unblinded assessment by the Data Safety Monitoring Board (DSMB).
🚩 Red Flags
- Potential efficacy signal: Interim analysis suggests the drug may not be performing as well as anticipated, which threatens the primary objective of demonstrating superiority over placebo.
- Clinical trial uncertainty: The DSMB review could lead to protocol changes or study termination.
- Capital risk: The company's forward-looking statements explicitly mention 'the sufficiency of its capital resources and need for additional capital'.
📋 Key Facts
- Voluntary pause of Phase 3 enrollment in the EBO-301 trial evaluating epetraborole for MAC lung disease.
- Interim blinded aggregate analysis showed potentially lower than expected efficacy in the Phase 2 portion.
- The decision was not driven by safety concerns.
- Topline data from the Phase 2 part of the trial is expected in summer 2024.
- Phase 3 enrollment had reached nearly 100 patients prior to the pause.